OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration
LONDON, Oct. 7, 2026 /PRNewswire/ — OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product’s potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetration of tyrosine kinase inhibitors (TKIs). OB-001 is a highly selective and effective inhibitor of […]







